Literature DB >> 7279807

Response criteria for the prostate of the USA National Prostatic Cancer Project.

G P Murphy, N H Slack.   

Abstract

Response criteria developed by the national Prostatic Cancer Project to evaluate chemotherapy for advanced disease and as an adjuvant in early disease are described. Subjective and objective procedures and tests are used to compare pre- and post-treatment disease activity in advanced disease. These patients enter trials in demonstrated progression; hence stabilization of activity was considered a category of objective response. Other response categories include the rare complete response and less rare partial regression, with progression for non-responders. In adjuvant studies response indicators are the incidence of recurring disease and length of disease-free-interval.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7279807     DOI: 10.1002/pros.2990010313

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

2.  Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

Authors:  N J Vogelzang; V J Lanzotti; B Muntean; R R Blough
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

3.  Dietary folate deficiency blocks prostate cancer progression in the TRAMP model.

Authors:  Gaia Bistulfi; Barbara A Foster; Ellen Karasik; Bryan Gillard; Jeff Miecznikowski; Vineet K Dhiman; Dominic J Smiraglia
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-11

4.  Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.

Authors:  S Naito; T Ueda; S Kotoh; J Kumazawa; K Itoh; K Sagiyama; T Omoto; S Andoh; Y Hasegawa; Y Fujisawa
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group.

Authors:  H Sakai; Y Minami; H Kanetake; Y Saito
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Phase II clinical study of pirarubicin in hormone resistant prostate cancer.

Authors:  B L Rapoport; G Falkson
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

7.  The essential role of methylthioadenosine phosphorylase in prostate cancer.

Authors:  Gaia Bistulfi; Hayley C Affronti; Barbara A Foster; Ellen Karasik; Bryan Gillard; Carl Morrison; James Mohler; James G Phillips; Dominic J Smiraglia
Journal:  Oncotarget       Date:  2016-03-22

8.  Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model.

Authors:  Hayley C Affronti; Mark D Long; Spencer R Rosario; Bryan M Gillard; Ellen Karasik; Christoph S Boerlin; Anthony J Pellerite; Barbara A Foster; Kristopher Attwood; Roberto Pili; John H Wilton; Moray J Campbell; Dominic J Smiraglia
Journal:  Oncotarget       Date:  2017-10-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.